Absci logo

Absci

ABSI | NASDAQ
Chart Builder DCF Calculator
$7.47
-$0.98 (-11.60%)
At close: Nov 16, 2026, 4:00 PM ET
$7.55
+$0.08 (+1.12%)
After-hours: Nov 16, 2026, 7:58 PM ET
-11.60%

Rating

Updated: Nov 16, 2026
21.2
-3.0 pts
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #978/1021 (Top 96%)

Key Statistics

Market Data

Market Cap $1.29B
1D Range
7.29 8.15
52W Range
2.30 12.10

Valuation (TTM)

PE -9.46
PB 5.90
EV/EBITDA -9.76

Valuation (NTM)

Forward PE N/A
Forward PEG 2.21
Price Target $14.50
Loading financial charts...

Profile

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creat...

Sector Healthcare
Industry Biotechnology
Employees 140
IPO Date Jul 22, 2021
Fiscal Year January - December

Latest News

Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript

4 days ago · seekingalpha.com

Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript
Absci Q3 Earnings Call Highlights

4 days ago · marketbeat.com

Absci Q3 Earnings Call Highlights
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates

4 days ago · zacks.com

Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results

4 days ago · globenewswire.com

Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline

4 days ago · globenewswire.com

Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

5 days ago · seekingalpha.com

Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Absci to Participate in Upcoming Investor Conferences

21 days ago · globenewswire.com

Absci to Participate in Upcoming Investor Conferences
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026

1 month ago · globenewswire.com

Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

2 months ago · globenewswire.com

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Earnings

Latest Earnings
Nov 12, 2026
EPS
-$0.19
Miss -0.57%
REV
$304K
Miss -53.79%
Next Earnings
Mar 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$14.00
Upside
+87.42%
Buy (7)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.